The Prevalence and Burden of Type 2 Inflammation in Patients With CRSwNP

• Review the inflammatory endotypes observed in CRSwNP, zooming in on the key role of type 2 cytokines, IL-4, IL-13, and IL-5
• Understand the underappreciated burden on health-related quality of life, and the importance of bringing patients into the decision-making process
• Define the concepts of statistical significance and clinical importance, and the advantages of considering clinically important symptom improvements in patients with CRSwNP
• Review evidence of improvements in olfaction with surgery and biologics from real-world effectiveness studies and randomized controlled trials, and safety of biologics in patients with CRSwNP

Join Stella Lee, MD, Peter Hellings, MD, PhD, and Wytske Fokkens, MD, PhD, as they discuss type 2 inflammation in CRSwNP, partnering with patients to improve outcomes, and real-world evidence of biologic effectiveness in CRSwNP.